

(51) International Patent Classification:
A61K 51/00 (2006.01)(21) International Application Number:
PCT/US2014/011047(22) International Filing Date:
10 January 2014 (10.01.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/752,350 14 January 2013 (14.01.2013) US
61/785,788 14 March 2013 (14.03.2013) US

(71) Applicant: MOLECULAR INSIGHT PHARMACEUTICALS [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: BABICH, John, W.; 277 West 10th Street, Apt. 7N, New York, New York 10014 (US). ZIMMERMAN, Craig; 31 North Street, Topsfield, Massachusetts 01983 (US). JOYAL, John; 88 Beech Avenue, Melrose, Massachusetts 02176 (US). LU, Genliang; 200 Swanton Street, Apt 405, Winchester, Massachusetts 01890 (US).

(74) Agents: VILLACORTA, Gilberto M. et al.; Foley & Lardner LLP, 3000 K Street N.W., Suite 600, Washington, DC 20007 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS





FIG. 1

(57) Abstract: Compounds according to Formula (I) and Formula (II) are potent inhibitors of PSMA. (I) or (II) Pharmaceutical compositions may include a complex of a radionuclide and a Formula (I) compound or a Formula (II) compound. Methods include using the radionuclide complex of a Formula (I) compound or a Formula (II) compound for treating or diagnosis of a disease or a condition associated with PSMA activity.





Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))